Corrigendum: The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis via Modulating Multiple Signaling Pathways in Mice

Front Pharmacol. 2021 Oct 7:12:777914. doi: 10.3389/fphar.2021.777914. eCollection 2021.

Authors

Yongqiang Ai¹, Wei Shi¹, Xiaobin Zuo¹, Xiaoming Sun¹, Yuanyuan Chen¹, Zhilei Wang¹, Ruisheng Li², Xueai Song³, Wenzhang Dai¹, Wenqing Mu¹, Kaixin Ding¹, Zhiyong Li¹, Qiang Li¹, Xiaohe Xiao^{1

3}, Xiaoyan Zhan^{1

3}, Zhaofang Bai^{1

3}

Affiliations

¹ Department of Hepatology, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China.
² Research Center for Clinical and Translational Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
³ China Military Institute of Chinese Materia, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China.

Abstract

[This corrects the article DOI: 10.3389/fphar.2021.655531.].

Keywords: TGF-β1/Smads signaling pathway; combined pharmacotherapy; hepatic fibrosis; schisandrol B; wedelolactone.

Copyright © 2021 Ai, Shi, Zuo, Sun, Chen, Wang, Li, Song, Dai, Mu, Ding, Li, Li, Xiao, Zhan and Bai.

Publication types

Published Erratum